GlassScriptPhysician profile
Samuel Amankwah
NPI 1457912594
$1,440.45
in general payments reported to CMS, 2019-2025
21 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $404 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $56.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.14 |
| Education | $56.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $308.76 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $192.29 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $118.62 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $98.15 | 2025 | Tymlos |
| Dexcom, INC. | $95.45 | 2024 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $76.48 | 2025 | Isturisa |
| Amgen INC. | $64.62 | 2025 | Repatha, Tepezza |
| Corcept Therapeutics | $59.34 | 2025 | Korlym |
| Medtronic, INC. | $49.35 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $41.96 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $40.40 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $39.08 | 2025 | |
| Lilly USA, LLC | $37.48 | 2025 | Jardiance, Zepbound, Mounjaro |
| Ascendis Pharma Endocrinology INC | $36.69 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $36.32 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $34.71 | 2025 | Twiist |
| Averitas Pharma INC. | $29.71 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $25.09 | 2025 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Almatica Pharma LLC | $17.21 | 2025 | Teriparatide |
| Insulet Corporation | $14.70 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Amankwah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.